A Bence Jones protein urine test looks for abnormal monoclonal immunoglobulin light chains in urine. These proteins are usually made by a single clone of plasma cells and are most closely associated with multiple myeloma and related plasma-cell disorders. Bence Jones proteins are not the same as ordinary urine protein such as albumin. They are free kappa or lambda light chains small enough to pass through the kidney filter and enter urine when produced in excess. Modern evaluation usually combines blood tests—serum protein electrophoresis, immunofixation, and serum free light chains—with urine testing when clinically appropriate. A positive urine result does not by itself prove multiple myeloma, because monoclonal light chains can occur in other monoclonal gammopathies. Likewise, a negative random urine test cannot exclude myeloma. Interpretation depends on the test method, the amount and type of monoclonal protein, kidney function, blood results, bone marrow findings, imaging, and whether there is organ damage.
- What it detects: Bence Jones protein means a monoclonal free kappa or lambda light chain found in urine.
- Normal result: No monoclonal light-chain band should be detected; ordinary urine may still contain small amounts of other proteins.
- Positive result: A monoclonal urine light chain raises concern for a plasma-cell or B-cell disorder, especially multiple myeloma, but needs confirmatory evaluation.
- Best sample depends on purpose: A 24-hour urine collection can quantify monoclonal protein, while urine immunofixation identifies its type.
- Kidney symptoms matter: Light chains can injure the kidneys, so reduced urine output, swelling, severe weakness, dehydration, or rapidly worsening kidney tests need prompt clinical review.
Table of Contents
- What Bence Jones Protein Is
- Why the Urine Test Is Ordered
- Test Methods and Urine Collection
- Understanding Positive, Negative, and Quantitative Results
- Multiple Myeloma, Light Chains, and Kidney Risk
- How Urine Testing Fits With Blood Tests
- Follow-Up and Next Steps
What Bence Jones Protein Is
Antibodies, also called immunoglobulins, are built from heavy chains and light chains. Each antibody normally contains two heavy chains and two light chains. The light chains are either kappa or lambda. Healthy plasma cells make many different antibodies, so the blood contains a broad mixture of immunoglobulins and small amounts of free light chains.
A plasma-cell disorder can change that pattern. If one abnormal plasma-cell clone expands, it may produce a large amount of one identical immunoglobulin or one type of free light chain. That abnormal single-clone protein is called a monoclonal protein, M-protein, or paraprotein. When the monoclonal product consists of free light chains that pass into urine, the traditional term is Bence Jones protein.
This distinction is important because a standard urine dipstick is designed mainly to detect albumin. It can miss substantial free light-chain proteinuria. A person can therefore have a weak or even negative dipstick while a more specific electrophoresis or immunofixation test detects monoclonal light chains.
Bence Jones proteins are most strongly linked with multiple myeloma, particularly light-chain myeloma, but they can also appear in other monoclonal gammopathies. These include monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma, AL amyloidosis, some lymphomas or leukemias, and monoclonal gammopathy of renal significance.
A related urine free light chains test measures free kappa and lambda chains, while urine electrophoresis and immunofixation determine whether the protein pattern is monoclonal.
Why the Urine Test Is Ordered
Clinicians order Bence Jones protein testing when they need to look for or characterize a monoclonal plasma-cell disorder. The test is not a population cancer-screening test. It is usually prompted by symptoms, abnormal blood tests, kidney disease, unexplained proteinuria, or an already established diagnosis.
Possible reasons for testing include:
- unexplained anemia, bone pain, fractures, high calcium, or recurrent infections;
- reduced kidney function without a clear explanation;
- elevated total protein or an abnormal protein gap in blood;
- an M-spike or suspicious band on serum protein electrophoresis;
- an abnormal serum free light-chain ratio;
- unexpectedly high urine protein with little albumin on a standard urine test;
- evaluation for AL amyloidosis or another monoclonal gammopathy;
- baseline measurement or response monitoring in a person with measurable urine monoclonal protein.
Multiple myeloma is diagnosed from a combination of findings, not from Bence Jones protein alone. Current diagnostic criteria require evidence of a clonal plasma-cell disorder plus a myeloma-defining event. These events can include classic organ damage—hypercalcemia, renal impairment, anemia, or bone lesions—or certain high-risk biomarkers.
Urine monoclonal protein can contribute to that assessment. For example, one biomarker-defined route to a multiple myeloma diagnosis involves an involved-to-uninvolved serum free light-chain ratio of at least 100, with the involved free light chain at least 100 mg/L; current criteria also account for a urine monoclonal protein level of at least 200 mg per 24 hours in this context. This threshold is a diagnostic-criteria detail, not a universal definition of a “positive Bence Jones test.”
Test Methods and Urine Collection
“Bence Jones test” can refer to several laboratory approaches. Older heat-precipitation methods are largely historical. Modern laboratories use protein electrophoresis, immunofixation, and light-chain assays because they identify monoclonal proteins more specifically.
Urine protein electrophoresis
Urine protein electrophoresis (UPEP) separates urinary proteins according to their movement in an electric field. A narrow discrete peak or band can suggest a monoclonal protein. With a properly collected 24-hour sample, UPEP can also quantify how much monoclonal protein is excreted per day.
Urine immunofixation
Urine immunofixation is more sensitive for identifying a small monoclonal protein and determines whether it is kappa or lambda. It is often used to confirm and type an abnormal band rather than simply measure total urine protein.
Random versus 24-hour urine
A random or clean-catch urine sample may be used for qualitative detection in some settings. For quantification of daily monoclonal protein excretion, a 24-hour urine collection is preferred. Collection instructions usually follow the standard 24-hour approach: discard the first urine at the start time, collect every subsequent void for 24 hours, and include the final void at the same time the next day.
The collection must be complete. Missed urine can underestimate protein excretion, while an overly long collection can overestimate a daily amount. Storage instructions vary, so use the container and directions supplied by the laboratory.
No special diet is usually required for Bence Jones testing, but the clinician should know about recent contrast studies, severe dehydration, urinary tract infection, heavy exercise, and medicines that could affect general urine-protein testing or kidney function.
The laboratory may report several numbers from the same collection: total urine volume, total protein, an electrophoretic monoclonal-protein concentration, and a calculated amount per 24 hours. These values answer different questions. Total urine protein includes monoclonal light chains plus other proteins, while the monoclonal component estimates the abnormal clone-related protein specifically. A dilute urine sample can have a low concentration per deciliter yet still contain a clinically meaningful 24-hour total if the urine volume is large. For that reason, a concentration from a random specimen should not be treated as interchangeable with a properly measured 24-hour excretion value.
Understanding Positive, Negative, and Quantitative Results
A negative Bence Jones result means the laboratory did not detect a monoclonal free light chain in that urine specimen using that method. It does not guarantee that no plasma-cell disorder exists. Low-level secretion may be below the assay’s detection limit, kidney handling may affect urine concentration, or the disorder may produce an intact immunoglobulin rather than substantial urinary free light chains.
A positive result means a monoclonal light chain has been detected. The report may identify kappa or lambda. A single restricted light-chain type supports clonality, but the diagnosis still depends on blood tests, bone marrow evaluation, imaging, and clinical features.
| Report finding | General meaning | Typical follow-up |
|---|---|---|
| No monoclonal light chain detected | No Bence Jones protein identified in that sample | Interpret with serum electrophoresis, immunofixation, and serum free light chains if suspicion remains |
| Monoclonal kappa light chain | A single kappa-producing clone is likely | Evaluate for plasma-cell or B-cell monoclonal gammopathy |
| Monoclonal lambda light chain | A single lambda-producing clone is likely | Evaluate for plasma-cell or B-cell monoclonal gammopathy |
| Quantifiable urine M-protein | Daily excretion can be measured and followed | Compare with prior values and other disease markers |
| Polyclonal or nonspecific protein pattern | Protein is present but not clearly from one clone | Investigate kidney disease, inflammation, or other causes as appropriate |
There is no single “normal Bence Jones level” analogous to a routine chemistry reference range. The desired qualitative result is no monoclonal protein detected. When a 24-hour monoclonal protein amount is reported, clinicians interpret the number in the context of diagnostic criteria or response criteria rather than against one universal healthy range.
A report may also describe a faint restricted band that is detectable by immunofixation but too small to quantify reliably by electrophoresis. “Present but not quantifiable” is different from a measured 24-hour M-protein value and should not be forced into a numerical estimate. Conversely, a total urine protein result can be high for reasons unrelated to the monoclonal clone, such as albumin loss from diabetic kidney disease. The electrophoretic and immunofixation pattern is what tells the laboratory whether a monoclonal light chain is actually present.
Kidney function can change the relationship between blood and urine results. Diseased tubules may reabsorb filtered light chains differently, and severe renal impairment can alter serum free light-chain concentrations even without a large change in the plasma-cell clone. Hematologists therefore interpret serum and urine measurements together rather than expecting a fixed conversion between them.
Changes over time can be useful in a patient whose disease produces measurable urine light chains. A falling amount may support treatment response. A reappearing or rising monoclonal protein can raise concern for biochemical relapse or progression, but trends should be confirmed according to the clinical protocol being used.
Multiple Myeloma, Light Chains, and Kidney Risk
Free light chains are clinically important because they can be directly harmful to the kidneys. When production overwhelms normal reabsorption in the kidney tubules, light chains enter urine. Some can combine with other proteins and form obstructing casts in the tubules, contributing to light-chain cast nephropathy, a major cause of acute kidney injury in multiple myeloma.
Other monoclonal light-chain disorders can injure the kidneys through different mechanisms, including deposition in tissues or amyloid formation. The severity of kidney disease therefore does not always track neatly with the total amount of protein on a routine urine dipstick.
Warning findings that deserve prompt medical assessment include a sudden rise in creatinine, markedly reduced urine output, new swelling, severe dehydration, confusion, profound weakness, or symptoms of high calcium. In a person with suspected myeloma, kidney injury can worsen quickly and may affect treatment choices.
Hydration is often important during evaluation, but people with heart failure, advanced kidney disease, or other fluid restrictions should not aggressively increase fluids without medical guidance. Avoiding nonsteroidal anti-inflammatory drugs and unnecessary contrast exposure may also be relevant in some patients, but medication decisions should be individualized.
Bence Jones protein is therefore both a tumor marker and a potential mediator of organ injury. Finding it can help characterize the abnormal clone while also signaling a need to assess kidney function carefully.
How Urine Testing Fits With Blood Tests
Modern monoclonal-gammopathy evaluation relies heavily on blood testing because serum methods are sensitive and easier to repeat. A common initial panel includes serum protein electrophoresis (SPEP), serum immunofixation, and serum free light chains. These tests detect different aspects of monoclonal protein production and work best as a group.
SPEP can reveal and quantify an M-spike when enough intact monoclonal immunoglobulin is present. Serum immunofixation identifies the immunoglobulin type. Serum free light-chain testing measures unbound kappa and lambda chains and calculates their ratio, which is particularly useful in light-chain and low-secretory disease.
For many patients, this serum combination has reduced the need for 24-hour urine testing as the first screening step. Urine testing still has important roles, however, especially when clinicians need to document urinary monoclonal protein, evaluate certain renal presentations, assess AL amyloidosis, or apply disease-specific response criteria.
A blood M-protein test and a urine Bence Jones result should not be expected to match numerically. The kidneys filter and metabolize light chains, so urine excretion depends not only on production by the plasma-cell clone but also on kidney function and tubular handling.
This is why a clinician may see a very abnormal serum free light-chain concentration with relatively little urine protein, or substantial urinary light chains in a person whose routine urine albumin test is unimpressive.
Follow-Up and Next Steps
A positive Bence Jones protein result usually leads to characterization of the monoclonal gammopathy, not an immediate assumption of cancer. The next steps depend on what is already known.
If this is the first abnormal finding, clinicians commonly review a complete blood count, calcium, creatinine and estimated kidney function, serum protein electrophoresis, serum immunofixation, quantitative immunoglobulins, and serum free light chains. Depending on the pattern, referral to hematology may lead to bone marrow biopsy and imaging for bone lesions or plasmacytomas.
If multiple myeloma is already diagnosed, the urine result may be used as a baseline or response marker. Ideally, serial measurements use the same collection method and laboratory so that changes are easier to interpret. Treatment response is assessed across multiple dimensions; a low urine M-protein alone does not establish complete remission because residual monoclonal protein may be detectable by more sensitive tests.
A positive result can also uncover disorders that are not multiple myeloma. MGUS, for example, is a premalignant monoclonal gammopathy that is monitored rather than treated in many cases. AL amyloidosis requires its own organ-focused evaluation. Monoclonal gammopathy of renal significance may cause important kidney injury even when the plasma-cell clone is too small to meet myeloma criteria.
For patients being monitored over time, trends need the same clinical context. A rising urine monoclonal-protein value can reflect increasing light-chain production, but a change in kidney function or an incomplete 24-hour collection can distort the apparent trend. If a result changes unexpectedly, clinicians may repeat the collection and compare it with serum free light chains, creatinine, and other disease markers before labeling it progression. Modern response criteria also use multiple measurements rather than a single isolated urine value.
The practical takeaway is simple: Bence Jones protein means monoclonal light chains in urine, not automatically multiple myeloma. The finding becomes meaningful when paired with the quantity of protein, the light-chain type, serum studies, kidney function, symptoms, imaging, and bone marrow findings.
References
- Multiple Myeloma: 2026 Update on Diagnosis, Risk-Stratification and Management 2026 (Review)
- Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management 2024 (Review)
- A review of clinical guidelines, laboratory recommendations and external quality assurance programs for monoclonal gammopathy testing 2023 (Review)
- Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy. Part I: Update on laboratory tests for the study of monoclonal gammopathies 2023 (Position Statement)
- Urine Protein Immunofixation Electrophoresis: Free Light Chain Urine Immunofixation Electrophoresis Is More Sensitive than Conventional Assays for Detecting Monoclonal Light Chains and Could Serve as a Marker of Minimal Residual Disease 2023
- Quantitative Bence-Jones protein test 2024
Disclaimer
This article provides general educational information and does not diagnose multiple myeloma or another monoclonal gammopathy. A positive or negative Bence Jones urine result must be interpreted with serum tests, kidney function, symptoms, and other clinical findings. Seek prompt medical care for rapidly reduced urine output, severe weakness, confusion, dehydration, or other signs of significant kidney or metabolic illness.
